KOD vs MENS: fair value comparison
Kodiak Sciences Inc. and Jyong Biotech Ltd. · Updated 2026-10-19
KOD has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MENS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, KOD currently ranks higher by quality score.
| KOD | MENS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $85.75 | $1.84 |
| 12-month range | $16.90–$99.87 | $1.46–$60.80 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #295 of 301 Healthcare | #296 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | High | Low |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: KOD fair value analysis · MENS fair value analysis